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Primary breast lymphomas (PBLs) represent less than 1% of all breast malignancies. Intravascular large B-cell lymphoma
(ILBCL) is a rare, aggressive form of extranodal lymphoma. Breast involvement has only been described in the literature
once previously. ILBCL is characterized by the proliferation of tumour cells within the lumen of small vessels of involved
organs, resulting in their eventual occlusion. Clinical features are often vague, diagnosis is difficult and delayed, and
prognosis is usually poor. We report the first ever case of synchronous ILBCL and invasive ductal carcinoma (IDC) of the
breast in a patient presenting with pyrexia of unknown origin and altered mental status who underwent modified
radical mastectomy and subsequent chemotherapy, and review the literature regarding intravascular large B-cell
lymphoma, PBLs and synchronous carcinomas and lymphomas of the breast.
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The breast is one of the least common sites for malig-
nant extranodal lymphomas. Primary breast lymphomas
(PBLs) constitute less than 1% of all breast neoplasms,
and are usually non-Hodgkin’s lymphomas. A wide var-
iety of histological subtypes have been reported, and it is
thought that patients with PBLs have a stage-for-stage
prognosis similar to other patients with lymphomas of
the same histology that present at other sites [1]. PBLs
usually present as a painless, solitary mass, often with asso-
ciated ipsilateral axillary lymphadenopathy. Multiple masses
and diffuse breast enlargement (unilateral or bilateral) have
also been reported. Skin retraction, erythema, peau d’or-
ange and nipple involvement are rare. The most frequent
mammographic appearance is a well-circumscribed uncal-
cified mass. Other radiographic features include amorphous
or spiculated uncalcified masses and diffusely increased
parenchymal density. Ultrasound usually reveals hypoe-
choic lesions with well-defined borders that lack significant* Correspondence: christopher.ho03@imperial.ac.uk
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reproduction in any medium, provided the orposterior enhancement or acoustic shadowing that may be
confused with a benign cyst [2].
Intravascular large B-cell lymphoma (ILBCL) is a rare,
high-grade extranodal diffuse B-cell lymphoma that has
only been described in the breast once previously in a pa-
tient who had bilateral symmetrical breast engorgement
with thickened, peau d’orange skin [3]. The median age at
diagnosis is 67 years and it has a male:female sex distribu-
tion of 1.3:1. ILBCL may affect virtually any organ and is
characterized by the clonal proliferation of malignant lym-
phocytes within the lumen of small vessels, resulting in
their consequent blockage. Parenchyma, lymph nodes and
the reticuloendothelial system are relatively spared [4]. In
contrast to other lymphomas that present with lymphaden-
opathy and tumour mass, ILBCLs present heterogeneously
depending on the organ affected. Common clinical features
include pyrexia of unknown origin, generalized fatigue, cu-
taneous lesions (including rashes, plaques, nodules, ulcers
and hyperpigmentation) and neurological changes (includ-
ing altered consciousness, sensorimotor deficits, seizures,
paresis and dementia). Gastrointestinal symptoms, an-
aemia, thrombocytopenia, oedema and dyspnoea have also
been reported. Due to its wide-ranging, non-specific signs
and symptoms, the diagnosis of ILBCL is often difficultThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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aggressive nature, disseminated disease is often present
when ILBCL is ultimately recognized, resulting in a dismal
prognosis [4].
We describe the first case of synchronous ILBCL and in-
vasive ductal carcinoma (IDC) of the breast, and illustrate
the diagnostic pitfalls and therapeutic dilemmas com-
monly encountered by clinicians when faced with ILBCL
and synchronous tumours.
Case presentation
A 75-year-old Malay woman with a background of dia-
betes mellitus, hypertension, hyperlipidaemia and endo-
metrial carcinoma who had undergone curative resection
and was now in remission presented with a 6-month his-
tory of flu-like symptoms and intermittent swinging pyr-
exia associated with chills and rigors. The patient’s family
had also noticed that she was becoming increasingly con-
fused and drowsy.
The patient had no gastrointestinal, genitourinary or re-
spiratory symptoms, and did not have signs of meningitis.
Physical examination was normal. Extensive infective, ma-
lignancy and autoimmune screens did not yield any posi-
tive results. Repeated computed tomography (CT) and
magnetic resonance imaging (MRI) of the brain were un-
remarkable. Bone marrow biopsy revealed a hypercellular
marrow without any evidence of haematolymphoid malig-
nancy or metastasis and was sent for karyotyping. Bone
marrow lymphocytes showed normal morphology and fea-
tured a diffuse interstitial infiltrate comprising CD3 posi-
tive T-cells with fewer CD20 positive B-cells.Figure 1 Mammogram. (A) Craniocaudal and (B) mediolateral oblique vie
with associated architectural distortion in the lower central breast highly su
in the lower inner quadrant and a few calcified oil cysts in the upper outerCT of the thorax, abdomen and pelvis was unremarkable
except for a 16 mm lesion in the right inferior breast. Mam-
mography confirmed an irregular 12 × 11 × 9 mm spicu-
lated mass in the 6 o’clock position with ill-defined margins
(Figure 1). Fine needle aspiration cytology was suggestive of
malignancy, and positron emission tomography (PET)-CT
showed a hypermetabolic right breast nodule suspicious for
primary breast tumour (Figure 2). No other fluorodeoxyglu-
cose (FDG)-avid lesions were noted.
As extensive investigations had failed to identify the rea-
son for the patient’s symptoms, the presumptive diagnosis
was that of a breast carcinoma-related paraneoplastic syn-
drome causing fever and confusion. A modified radical
mastectomy with level II axillary clearance was performed,
and the fever resolved immediately after surgery. The pa-
tient also became more alert, albeit only for the first 2
postoperative days before becoming drowsy again.
Histological analysis confirmed a 20 mm IDC (grade I,
oestrogen receptor (ER) and progesterone receptor (PR)
positive, human epidermal growth factor receptor 2 (HER2)
negative) with minimal ductal carcinoma in situ. In
addition, the small- and medium-sized vessels surrounding
the focus of IDC and the breast tissue revealed large atyp-
ical intravascular cells (Figure 3A,B,C). These atypical cells
were CD20 positive B-lymphocytes with small to moderate
amounts of cytoplasm and round to irregular, vesicular and
nucleolated nuclei with discernible mitoses (Figure 3D).
These large lymphoid cells were strongly and diffusely re-
active to MUM-1, and showed weak positivity for CD5,
BCL6 and CD10. No expression was seen with cyclin D1,
CD23 and CD3. MIB1 proliferative index was more thanws of the patient’s right breast. There is a 19 mm spiculated mass
spicious for malignancy. There is also a partially calcified fibroadenoma
quadrant.
Figure 2 PET-CT. A 1.8 × 1.4 cm spiculated mildly FDG-avid right
breast nodule just below the level of the nipple is demonstrated
(maximum standardized uptake value 3.9). FDG, fluorodeoxyglucose;
PET-CT, positron emission tomography-computed tomography.
Figure 3 Histological analysis. (A) IDC (top right) with ILBCL (bottom cen
away from the IDC. Most of the blood vessels show darkly stained atypical
lymphoid cells within the blood vessels 200× magnification. (D) CD20 reac
IDC, invasive ductal carcinoma; ILBCL, intravascular large B-cell lymphoma.
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20 metaphases analyzed had complex structural abnormal-
ities, loss of X chromosome and trisomy 18. Thus, a unique
diagnosis of synchronous IDC and non-germinal centre
type ILBCL was made.
The patient was started on the rituximab, cyclophospha-
mide, hydroxydaunorubicin, Oncovin (vincristine) and
prednisolone (R-CHOP) chemotherapy regimen which led
to a sustained improvement in her mental state. Unfortu-
nately, the subsequent tumour lysis resulted in acute renal
failure requiring haemodialysis. Finally, the patient devel-
oped neutropenic sepsis, and passed on 2 weeks after com-
mencing chemotherapy.
Discussion
This case represented a significant diagnostic challenge
because of the patient’s non-specific clinical features, the
presence of a confounding synchronous IDC and the rar-
ity of ILBCL, especially in the breast. Similar to the previ-
ous reported case of ILBCL involving the breast [3], this
patient also satisfied the diagnostic criteria for primary
breast lymphomas, but did not have any signs or symp-
toms localizing to the breast. One of the differentials
entertained was a paraneoplastic syndrome, which results
from tumour secretion of substances that mimic the ef-
fects of endogenous hormones and cytokines, or from thetre) 130× magnification. (B) ILBCL in the surrounding breast tissue
lymphoid cells within their lumen 40× magnification. (C) Atypical
tive atypical large cells within the blood vessels 400× magnification.
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normal cells. Paraneoplastic syndromes involving the
breast are rare, and it is estimated that only 36% of such
patients have identifiable paraneoplastic antibodies [5].
Fever is one of the most common features, and is thought
to be cytokine-mediated. In addition, specific onconeural
autoantibodies such as anti-Ri, anti-Ro and anti-Yo, which
may form in response to the breast neoplasm, may also
target tissue antigens of the central and peripheral nervous
system [5,6]. However, in contrast to this case, the neuro-
logical manifestations described were motor, sensory and
visual with no impairment of consciousness.
Given its rarity and protean manifestations, the diagnosis
of ILBCL is one of considerable difficulty. Nevertheless,
ILBCL often presents with pyrexia of unknown origin, as
well as cutaneous and neurological features [4]. Neurora-
diological signs, however, are present in only half of patients
with neurological symptoms; CT is frequently normal in
patients with neurological manifestations of ILBCL and is
therefore generally considered non-diagnostic, and MRI is
often normal or shows non-specific hyperintense white
matter lesions suggestive of small vessel ischaemic disease
or demyelination [7]. As illustrated in this case, PET-CT
may also fail to demonstrate cerebral localization of ILBCL.
Such false negatives have also been reported in other stud-
ies in patients with neurological symptoms [4,8]. Bearing
this in mind, a low threshold for biopsy of suspicious le-
sions should be maintained in the appropriate clinical con-
text, as histological diagnosis is paramount to the timely
and appropriate treatment vital to improving patient out-
come. The classic appearance and immunophenotype of
ILBCL is that of large malignant CD20, CD19, CD10, CD5
and CD79a positive B-lymphocytes filling small vascular
lumens. In addition, chromosomal analysis may reveal
abnormalities in 1p and trisomy 18 [4,9].
Numerous theories attempt to explain the pathogen-
esis of synchronous carcinoma and lymphoma of the
breast. Patients with lymphoma are known to be chron-
ically immunosuppressed, which may predispose to the
development of a second malignancy [10]. It has also been
suggested that the antigenic stimulation from an as yet un-
defined breast carcinoma antigen may drive the develop-
ment of a mucosa-associated lymphoid tissue (MALT)
lymphoma, analogous to the effect of chronic Helicobacter
pylori infection on the pathogenesis of gastric MALT
lymphomas [11]. Another postulated mechanism is that
both tumours share the same aetiological factors, with
mutation in the ataxia telangiectasia mutated (ATM)
tumour suppressor gene [12], as well as infection with the
Epstein-Barr virus (EBV) [13] and mouse mammary
tumour virus (MMTV) [14] all currently implicated.
Mastectomy has traditionally been considered the gold
standard treatment for PBLs, however, this has now shown
to offer no survival benefit or protection from recurrence[2]. Chemotherapy, typically an anthracycline-based re-
gime with or without rituximab has emerged as the main-
stay of treatment, and can be combined with radiotherapy
in patients with intermediate or high grade lymphomas
[1,2,15]. There are no randomized controlled trials com-
paring treatment for patients with ILBCL, however, as dis-
semination is common at diagnosis, aggressive systemic
chemotherapy is usually warranted. Methotrexate, either
intrathecal or high-dose systemic, should be incorporated
if central nervous system involvement is present [16]. The
addition of rituximab has been shown to significantly im-
prove clinical outcomes [4,17], and autologous stem cell
transplantation has been shown to be effective in young
patients with good performance status [17]. Because of the
rarity of synchronous carcinoma and lymphoma of the
breast, there is no consensus on treatment in such cases
and it remains uncertain if such synchronous tumours
should be viewed as two distinct clinical entities with cor-
responding separate treatments, or as a single disease with
therapy that encompasses both tumour types.
This unique synchronous tumour comprising of an IDC
and ILBCL in a patient presenting with pyrexia of un-
known origin and altered mental status highlights the dif-
ficulties in diagnosing ILBCLs as well as synchronous
tumours in general. Although the optimal management
for such synchronous tumours is still a matter for further
studies, adequate histological assessment is vital to ensure
appropriate treatment. Finally, additional investigation
into the pathogenesis of synchronous carcinoma and
lymphoma of the breast may lead to novel preventative
and therapeutic strategies for such synchronous tumours
as well as for its individual constituent neoplasms.
Conclusion
We report the first case of synchronous carcinoma and
ILBCL of the breast. ILBCL is rare, and has only been de-
scribed in the breast once previously. Its clinical spectrum
is broad, and a high degree of suspicion is required to seek
early biopsy to establish histological diagnosis. Timely, ag-
gressive, systemic chemotherapy has been shown to signifi-
cantly improve outcomes. The development and treatment
of synchronous breast carcinomas and lymphomas remains
uncertain, and further studies should be encouraged.
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